David Berry joined Flagship in 2005 where he focuses on innovating, entrepreneuring, and investing in new ventures in life sciences and sustainability.  He is a founder of Flagship portfolio companies LS9, Joule Unlimited, Eleven Biotherapeutics, Seres Health, Pronutria, among others.  David was founding CEO of Joule and Pronutria.  He was also a Board member of Flagship portfolio company CGI Pharmaceuticals (acquired by Gilead in 2010), and currently serves on the boards of Joule, Eleven, Seres and Pronutria. David previously completed his combined MD-PhD from Harvard Medical School and the MIT Biological Engineering Division in just over 5 years. 

He has been recognized with over 50 awards and honors as an innovator including receiving the prestigious Lemelson-MIT Student Prize for invention and innovation, being named the Innovator of the Year by Technology Review, and being selected by the US State Department as 1 of 12 Innovators Helping to Reshape Realty.  He also speaks across the globe on topics including innovation, sustainability, biotechnology, and entrepreneurship, including at the National Academies, for the Prince of Girona Foundation, and at Google Solve for X.  David previously served on the MIT Corporation, its Board of Trustees, and currently serves on the boards of multiple not-for-profits in education and the arts, and has been appointed to the United Nations Sustainable Development Solution Network Leadership Council.

Click here for a recent Boston Magazine profile on David Berry.